Berwyn, PA, April 30, 2015: QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced the election of Dr. Peter Davies to its Scientific Advisory Board. This appointment follows the recent Series A funding.
“We are thrilled to have Peter on our Scientific Advisory Board,” said Maria L.Maccecchini, Chief Executive Officer of QR. “Peter brings a wealth of knowledge in the field of Alzheimer’s disease. His experience will be invaluable to QR as it undertakes the continued clinical studies of its lead compound, Posiphen, in Alzheimer’s and Parkinson’s patients.”
Peter Davies added: “I am very excited to be associated with QR Pharma, and I look forward to a very productive association.”
Peter Davies, PhD
Director, Litwin-Zucker Research Center for the Study of Alzheimer’s Disease,
The Feinstein Institute for Medical Research
Professor, Pathology and Neuroscience, Hofstra North Shore-LIJ School of Medicine
Dr. Davies’ early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease — Aricept, Exelon and Razodyne. For more than 35 years, Dr. Davies’ research has been focused on biochemistry of Alzheimer’s disease. He has published over 250 research papers and has been particularly interested in the development of new treatments and diagnostic tests for Alzheimer’s disease. He has received numerous awards for his research, including the City of New York Liberty Medal, a Lifetime Achievement Award from the International Congress on Alzheimer’s disease (ICAD) and the first Metropolitan Life Foundation Prize. Dr Davies has also received two MERIT awards from the National Institutes of Health (NIMH, 1989-1999, and NIA 2003-2013).
Most recently he has been the recipient of the 2015 Potamkin Prize for Alzheimer’s Research.
The Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases was established in 1988 and is sponsored by the American Academy of Neurology. The prize is awarded for achievements on emerging areas of research in Pick’s disease, Alzheimer’s disease and other dementias.The award includes a medallion, $100,000 prize, and a lecture at the American Academy of Neurology.
Posiphen® is in clinical development as an oral treatment for Alzheimer’s disease (AD). It is a small orally active compound with high blood brain barrier permeability, which lowers amyloid precursor protein (APP) levels. QR conducted a trial in patients with mild cognitive impairment (MCI) to confirm Posiphen’s mechanismof actionin humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP and tau by about 40%, approaching the levels found in healthy volunteers.
About QR Pharma
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs: Posiphen for early stage Alzheimer’s and Parkinson’s Disease, and BNC for advanced AD.
QR has successfully completed Phase I clinical trials with Posiphen and is conducting other clinical and pre-clinical work in Traumatic Brain Injury (TBI) for the US Army. QR has recently been chosen for a human trial in Alzheimer’s patients in a NIH sponsored clinical trial. www.qrpharma.com.
Certain statements in this press release or made by management from time to time regarding QR Pharma that are not historical facts are “forward-looking statements,” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements.